Skip to content


Volume 18 Supplement 1

19th Annual SCMR Scientific Sessions

  • Poster presentation
  • Open Access

Prognostic value of late gadolinium enhancement cardiac magnetic resonance in hypertrophic cardiomyopathy: a meta-analysis

  • 1,
  • 2,
  • 3,
  • 3 and
  • 1
Journal of Cardiovascular Magnetic Resonance201618 (Suppl 1) :P117

  • Published:


  • Cardiovascular Magnetic Resonance
  • Cardiac Magnetic Resonance
  • Sudden Cardiac Death
  • Late Gadolinium Enhancement
  • Hypertrophic Cardiomyopathy


Contrast-enhanced cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE) has emerged as an in vivo marker of myocardial fibrosis, although its significance in identifying high risk hypertrophic cardiomyopathy (HCM) patients remains unresolved. Previous meta-analyses have included studies with data involving overlapping patient populations, thus confounding effect estimates.


We searched PubMed and Web of Science for clinical trials that investigated the prognostic utility of LGE in HCM patients. We excluded studies with overlapping data. Pooled odds ratios (ORs), hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the role of LGE CMR in the risk stratification of HCM patients.


Five studies of unique cohorts were retrieved from 393 citations for the analysis. In total, 2993 patients (mean age = 54.6 years; median follow up = 36.8 months) were included. After synthesizing data, meta-analysis showed that the presence of LGE was associated with a significantly increased risk of sudden cardiac death (SCD)/aborted SCD (pooled OR = 3.42, 95%CI = 1.97-5.94; P < 0.001), cardiac death (pooled OR = 2.93, 95%CI = 1.53-5.61; P = 0.001), all-cause mortality (pooled OR=1.80, 95%CI = 1.21-2.69; P = 0.004), and a trend towards increased risk of heart failure death (pooled OR = 2.21, 95%CI = 0.84-5.80; P = 0.107). Three publications reported results with quantitative LGE. There was a significant relationship between the extent of LGE and risk of SCD (pooled HR 1.56/10% LGE, 95% CI = 1.33-1.82, p < 0.0001), all-cause mortality (pooled HR 1.29/10%LGE, 95% CI = 1.09-1.51, p = 0.002), heart failure mortality (pooled HR 1.61/10% LGE, 95% CI 1.21-2.13, p = 0.001), and cardiovascular mortality (pooled HR 1.57/10% LGE, 95% CI 1.30-1.89, p < 0.001). After adjusting for baseline characteristics, the extent of LGE remained a strong independent predictor for SCD events (pooled HRadjusted 1.36/10%LGE, 95% CI 1.10-1.69, p = 0.005).


Extensive LGE by CMR identifies high-risk HCM patients, and is an independent predictor of sudden death. Quantitative assessment of myocardial fibrosis by LGE can thus be a clinically useful tool to help risk stratify patients with HCM.
Figure 1
Figure 1

Forest plot of presence of LGE and risk of adverse events.

Authors’ Affiliations

Cyrus Tang Hematology Center and Ministry of Education Engineering Center of Hematological Disease, Suzhou, China
Cardiology, Toronto General Hospital, Toronto, ON, Canada
Cardiology, First Affiliated Hospital of Soochow University, Soochow, China


© Weng et al. 2016

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.